BioAdaptives, Inc. (BDPT)
| Market Cap | 30.76K -87.7% |
| Revenue (ttm) | 25.56K +3,424.7% |
| Net Income | -1.16M |
| EPS | -0.10 |
| Shares Out | 15.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,467,053 |
| Open | 0.0020 |
| Previous Close | 0.0019 |
| Day's Range | 0.0018 - 0.0026 |
| 52-Week Range | 0.0008 - 0.0700 |
| Beta | 1.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About BioAdaptives
BioAdaptives, Inc. investigates, markets, and distributes natural plant, fungi, and algal‑based products and medical devices for humans and animals. The company offers MyndMed for immediate cognitive enhancement, medium-term resilience and memory gains, and long-term neuroprotection and cognitive health; Zeranovia, a weight loss enhancer; Wynovia to help reduce the loss of lean muscle mass during dieting; and Xcellara, a regenerative wellness solution. It also provides canine products under the PawPa brand; dog chew products under the Regen bra... [Read more]
Financial Performance
In 2025, BioAdaptives's revenue was $18,278, an increase of 44.27% compared to the previous year's $12,669. Losses were -$1.56 million, 73.3% more than in 2024.
Financial StatementsNews
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT) ...
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circu...
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, In...
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor
Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptiv...
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform
LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital sto...
BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches
LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial man...
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas Follo...
BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara's Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and...
BioAdaptives Completes MyndSystem™ Platform with TruShield Certification of MyndRenew™, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity
Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value consumer segments Certification ...
BioAdaptives Launches MyndSystem™ Website — The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery
Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during the day...
BioAdaptives, Inc. Launches MyndRenew™ to Complete the 24-Hour Brain Performance Cycle
New Nighttime Supplement Targets What Happens — or Fails to Happen — While You Sleep New Nighttime Supplement Targets What Happens — or Fails to Happen — While You Sleep
BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing
Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand Comprehensive cognitive-support formula now available online; company scaling product...
BioAdaptives' MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety
Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes Unique nootropic formula blends botanical extracts, am...
BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. NeuroRush™ de...
BioAdaptives Announces National Launch of Pawpa™ Regen
Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation
BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements
Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials Regen Dog Chews are crafted to the highes...
Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial
LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. Th...
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors
Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years Harris, the Senior Vice President of Ath...
BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors
Frissora is recognized for his ability to lead organizations through complex challenges and deliver sustained value creation Frissora is recognized for his ability to lead organizations through comple...
BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders
LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT), a forward-thinking innovator in health and wellness solutions, is pleased to announce that FINRA has approved a di...
BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health
LAS VEGAS, Dec. 10, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTC: BDPT) is thrilled to announce the launch of Xcellara™ Stem Cell Activator, a groundbreaking supplement that harnesses th...
BioAdaptives, Inc.'s Board of Directors Approves a One-for-One Stock Dividend
LAS VEGAS, Dec. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT) Board of Directors has approved a dividend to all common stockholders. They will receive matching shares for all of...
BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™
LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia™.
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began f...
BioAdaptives, Inc. Announces Complete Product Overhaul with New Line of Scientifically Advanced Solutions
Innovative product launch signals the company's commitment to meeting market needs and delivering exceptional customer value Innovative product launch signals the company's commitment to meeting marke...